

Amendments to the Claims:

1. (previously presented) A method of evaluating the efficacy of a therapeutic or prophylactic treatment of *Chlamydia*-induced disease, comprising the steps of:

a) rationally selecting a particular mouse strain and identifying whether said strain is a low nitric oxide (NO) responder strain or a high NO responder strain when said strain is exposed to bacterial antigens;

b) rationally selecting a dose of *Chlamydia* to be administered to a test mouse of said strain;

c) if ~~appropriate~~ said mouse strain is a low nitric oxide responder, rationally selecting a feeding regimen with ~~appropriate~~ high levels of arginine and feeding said test mouse according to said regimen, and if said mouse strain is a high nitric oxide responder, performing at least one step selected from the group consisting of:

(i) rationally selecting a feeding regimen with low levels of arginine and feeding said test mouse according to said regimen;
and

(ii) ~~d) if appropriate,~~ treating said test mouse with an inhibitor of nitric oxide synthase-2 (NOS2);

[[e]] d) administering said dose of *Chlamydia* to said test mouse;

[[f]] e) administering said therapeutic or prophylactic treatment to said test mouse; and

[[g]] f) assessing the severity of chlamydial disease in said test mouse[[,]]

~~wherein the severity of chlamydial disease in said mouse differs from the severity of chlamydial disease in a reference mouse to which said therapeutic or prophylactic treatment was not administered.~~

2. (original) The method of claim 1, wherein said treatment is a prophylactic treatment and said step of administering said prophylactic treatment is performed before said step of administering *Chlamydia* to said mouse.

3. (original) The method of claim 1, wherein the step of administering *Chlamydia* to said mouse comprises administering between 1×10^5 and 1×10^6 IFU of *Chlamydia* to said mouse intranasally.

4. (canceled)

5. (canceled)

6. (canceled)

7. (previously presented) The method of claim 1, wherein said mouse strain is A/J.

8. (previously presented) The method of claim 7, wherein the step of rationally selecting a feeding regimen comprises selecting a diet high in protein and arginine.

9. (original) The method of claim 1, wherein the step of rationally selecting a dose of *Chlamydia* to be administered to said test mouse comprises evaluating the mouse strain from which said test mouse is selected to determine the LD₅₀ for said mouse strain when treated with *Chlamydia psittaci*.